Literature DB >> 18975022

Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008.

Patrick Müller1, Stephan Rosenkranz, Oliver Adam, Florian Custodis, Michael Böhm.   

Abstract

This article summarizes the results of a number of clinical trials in the field of cardiovascular medicine which were presented during the Hotline and Clinical Trial Update Sessions at the annual meeting of the European Society of Cardiology, held in Munich, Germany, from 30th August to 3rd September 2008. The data were presented by leading experts in the field with relevant positions in the trials. It is important to note that unpublished reports should be considered as preliminary data, as the analysis may change in the final publications. The comprehensive summaries have been generated from the oral presentation and the webcasts of the European Society of Cardiology and should provide the readers with the most comprehensive information on diagnostic and therapeutic developments in cardiovascular medicine.

Mesh:

Year:  2008        PMID: 18975022     DOI: 10.1007/s00392-008-0729-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  22 in total

1.  Ezetimibe and cancer--an uncertain association.

Authors:  Jeffrey M Drazen; Ralph B D'Agostino; James H Ware; Stephen Morrissey; Gregory D Curfman
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

2.  Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago.

Authors:  Yvonne P Clever; Stephan Rosenkranz; Michael Böhm; Bruno Scheller
Journal:  Clin Res Cardiol       Date:  2008-05-15       Impact factor: 5.460

3.  Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.

Authors:  Roberto Marchioli; Federica Barzi; Elena Bomba; Carmine Chieffo; Domenico Di Gregorio; Rocco Di Mascio; Maria Grazia Franzosi; Enrico Geraci; Giacomo Levantesi; Aldo Pietro Maggioni; Loredana Mantini; Rosa Maria Marfisi; G Mastrogiuseppe; Nicola Mininni; Gian Luigi Nicolosi; Massimo Santini; Carlo Schweiger; Luigi Tavazzi; Gianni Tognoni; Corrado Tucci; Franco Valagussa
Journal:  Circulation       Date:  2002-04-23       Impact factor: 29.690

4.  Analyses of cancer data from three ezetimibe trials.

Authors:  Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

Review 5.  The role of heart rate in the development of cardiovascular disease.

Authors:  J-C Reil; M Böhm
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460

Review 6.  The case for statin therapy in chronic heart failure.

Authors:  Pim van der Harst; Michael Böhm; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

7.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

8.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

9.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  2 in total

1.  Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more.

Authors:  S H Schirmer; A M van der Laan; M Böhm; F Mahfoud
Journal:  Clin Res Cardiol       Date:  2009-11       Impact factor: 5.460

2.  Altered nitric oxide/cGMP platelet signaling pathway in platelets from patients with acute coronary syndromes.

Authors:  Loredana Bergandi; Marco Cordero; Matteo Anselmino; Gaetana Ferraro; Laura Ravera; Paola Dalmasso; Corrado Moiraghi; Gian Paolo Trevi; Dario Ghigo; Amalia Bosia; Serena Bergerone
Journal:  Clin Res Cardiol       Date:  2010-05-14       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.